Acción COSMO PHARMACEUTICALS SA
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas COSMO Pharmaceuticals SA Swiss Exchange

Acciones

LU1202320294

Precio de cierre Swiss Exchange
Otros sitios de cotización
- CHF - Gráfico intradía de COSMO Pharmaceuticals SA
18/06 La suiza Cosmo Pharmaceuticals recibe el certificado de registro de fármaco para Lumeblue en China MT
03/06 Cosmo Pharmaceuticals registra pérdidas en el ejercicio fiscal de 2023; los ingresos disminuyen MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Cosmo's oral diagnostic drug Lumeblue receives approval of New Drug Application in China
Bourse Zurich: séance en manque d'impulsion en perspective
Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
Cosmo Pharmaceuticals N : oral diagnostic drug Lumeblue® receives approval of New Drug Application in China
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Written Proxy
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Proposed Amendments to the Renumeration Policy
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Notification of number of shares as of 6 June 2024
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Explanatory Notes
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Convening Notice
Cosmo Pharmaceuticals N : Written proxy – EGM 5 July 2024
Cosmo Pharmaceuticals N : Proposed Amendments to the Remuneration Policy – EGM 5 July 2024
Cosmo Pharmaceuticals N : Notification of number of shares 6 June 2024 – EGM 5 July 2024
Cosmo Pharmaceuticals N : Explanatory notes – EGM 5 July 2024
Cosmo Pharmaceuticals N : Convening notice – EGM 5 July 2024
Morning Briefing - Markt Schweiz
Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down
Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
Cosmo Pharmaceuticals N : reports excellent final Full Year 2023 financial results – Increases operating profit guidance for 2024 – Dividend of € 2.00 per share will be proposed at EGM on 5 July 2024
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción COPN
  4. Acción
  5. Noticias COSMO Pharmaceuticals SA
  6. Otros idiomas